Abstract: The disclosure provides pharmaceutical topical otic, ophthalmic, or nasal aqueous suspension formulations that comprise a corticosteroid; a chelating agent; a xanthan gum; an ionic tonicity agent; a pH from 5 to 6; and balance water. Such formulations comprise amounts of each of the xanthan gum and the ionic tonicity agent that together result in the formulation having: (i) a viscosity of from 4000 centipoises (“cps”) to 8000 centipoises (“cps”), and (ii) an osmolality of from 250 milliosmoles (“mOsm”) to 350 mOsm, and (iii) are readily redispersible.
Type:
Application
Filed:
May 25, 2022
Publication date:
January 4, 2024
Inventors:
William Hite, Nilesh Parikh, Kapil Swain, Jonathan Moreno
Abstract: The present invention provides an aqueous solution comprising difluprednate as the sole active ingredient, wherein the aqueous solution comprises 0.02% to 0.04% w/v difluprednate and an aqueous vehicle, wherein the aqueous solution is free of oil and wherein the aqueous solution is administered twice-a-day for 7 to 21 days to the subject and a method of reducing an adverse effect associated with an inflammatory disorder of eye in a subject in need thereof, using said aqueous solution.
Abstract: The present invention relates to an oral pharmaceutical composition comprising (i) a biologically active material conjugate in which a biological active material is conjugated with a biotin moiety, a fatty acid moiety, or a combination thereof, and (ii) an excipient, wherein the absorption rate of the biologically active material is remarkably increased, whereby conventional drugs difficult to orally administer, such as proteins or peptides, can be administered orally.
Type:
Application
Filed:
November 29, 2021
Publication date:
January 4, 2024
Inventors:
Ok Cheol JEON, Sung Mook LIM, Eun Ji PARK
Abstract: The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and/or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.
Abstract: A pharmaceutical composition and method are provided which may be used for the treatment and prevention of various infections, diseases, and conditions. Preferably, the composition and method may be used for preventing and treating of aging and aging associated disease and its use (or method). Preferably, the composition and method may be used for treating and prophylaxis of microbial infectious diseases and associated inflammatory disorders and its use (or method). The pharmaceutical composition according to the invention includes a therapeutic agent X or a pharmaceutically acceptable salt thereof; a therapeutic agent Y or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, in which the therapeutic agent X is a non-steroidal anti-inflammatory drug and the therapeutic agent Y is a fatty acid oxidation inhibitor.
Abstract: This document provides compounds that can inhibit CB1 activity within a mammal (e.g., a human), as well as the methods of using such compounds for treating diseases, disorders, and conditions such as obesity, fear, metabolic-related disorders, diabetes, dyslipidaemia, and atherosclerosis.
Abstract: Provided herein are compositions comprising cannabinoid cyclodextrin inclusion complex compressed with effervescing agents, and having enhanced dissolution, dispersion and shelf-life, as well as methods of use thereof. The methods include methods of producing cannabinoid inclusion complexes dispersed in solutions, and method of making cannabinoid-infused food products or beverages using the self-emulsifying compositions of cannabinoid cyclodextrin inclusion complex.
Abstract: A method of treating Alzheimer's disease and/or other neurodegenerative disorder in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.
Abstract: A method of treating epilepsy in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.
Abstract: A method of treating Tourette syndrome or a tic disorder in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a bioefficient rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.
Abstract: The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.
Abstract: Provided are compounds useful for treating, preventing, reducing the occurrence of, slowing the progression of, or reducing, ameliorating, or alleviating the symptoms associated with a condition selected from the group consisting of: presbyopia, cataract, transthyretin (TTR)-associated amyloidosis, myopia, or other conditions or disorders associated with the eye, including COMT inhibitors and pro-drugs thereof, and methods of using these compounds.
Type:
Application
Filed:
November 15, 2021
Publication date:
January 4, 2024
Inventors:
Santosh C. SINHA, Sridhar Govinda PRASAD, Marshall C. PETERMAN
Abstract: An adjuvant containing zinc aluminum risedronate, an immunogenic composition comprising the adjuvant and an immunogen, and uses of the adjuvant and the immunogenic composition.
Type:
Application
Filed:
November 15, 2021
Publication date:
January 4, 2024
Inventors:
Qinjian ZHAO, Xiaofen HUANG, Meifeng NIE, Zhigang ZHANG, Quan YUAN, Tianying ZHANG, Shaowei LI, Ningshao XIA
Abstract: This invention provides methods for treating a human subject afflicted with alcohol use disorder (AUD) comprising administering to the subject a therapeutically effective amount of a psilocybin-based compound.
Abstract: Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
Type:
Application
Filed:
April 11, 2023
Publication date:
January 4, 2024
Inventors:
Walter Martin GREGORY, Juan Carlos TERCERO, Robert E. COLEMAN, Roger GOMIS
Abstract: Provided is an oral soft gel capsule that includes a psychedelic compound. Also provided is a method of treating in a subject a disease or disorder ameliorated by a psychedelic compound, that includes orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a low dose (e.g., microdose or sub-therapeutic dose) of the psychedelic compound.
Type:
Application
Filed:
September 15, 2023
Publication date:
January 4, 2024
Inventors:
Tony LaRosa, Robert Davidson, David Reid
Abstract: The present invention relates to a nutritional composition comprising fucosylated human milk oligosaccharides for improving sleep maturation in a subject.
Type:
Application
Filed:
December 3, 2021
Publication date:
January 4, 2024
Inventors:
CLARA LUCIA GARCIA-RODENAS, JONAS HAUSER
Abstract: Disclosed are methods and compositions for treating proliferative cell diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that alters the pathways used for purine biosynthesis by inhibiting the biological activity of ARL13B and/or IMPDH proteins in conjunction with additional therapeutic agents such as alkylating agents.
Type:
Application
Filed:
September 15, 2023
Publication date:
January 4, 2024
Inventors:
Atique U. Ahmed, Jack M. Shireman, Cheol H. Park
Abstract: The subject invention is the novel use of an injectable pharmaceutical composition comprising tildipirosin for the treatment and prophylaxis of foot rot. The use of a single subcutaneous dose of tildipirosin has been demonstrated to effectively treat naturally occurring foot rot.
Type:
Application
Filed:
December 2, 2021
Publication date:
January 4, 2024
Applicant:
Intervet Inc.
Inventors:
Luis Fernando Vettorato, Mauricio Marques De Morais, Rafael Marin Chiummo, Heitor De Oliveira Arriero Amaral
Abstract: The present invention relates generally to chromosome maintenance and cell viability, and more specifically, to the identification of kinases the inhibition of which blocks telomere elongation. In one aspect, the present invention provides methods for treating cancer. The methods generally comprise the administration of agents that interfere with the lengthening of telomeres in cancer. In a specific embodiment, a method of treating cancer in a subject by interfering with lengthening of telomeres in cancer cells comprises administering to the cells an effective amount of an inhibitor of casein kinase 1 (CK1), wherein the administration of the inhibitor leads to progressive telomere shortening in the cancer cell, thereby treating cancer in the subject. In another embodiment, the method can further comprise administering to the cells an effective amount of an inhibitor of bromodomain-containing protein 4 (BRD4) and/or an inhibitor of the MEK/ERK pathway.
Abstract: The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5? LTR, wherein the 5? LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.
Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2?-deoxy-2?-fluoroarabinonucleotide (2?-FANA)-modified nucleotide sequence. In some embodiments, the 2?-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.
Type:
Application
Filed:
June 29, 2023
Publication date:
January 4, 2024
Applicants:
CITY OF HOPE, AUM LIFE TECH, INC., THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
Inventors:
John J. ROSSI, Masad J. DAMHA, Veenu AISHWARYA, Mayumi TAKAHASHI, Haitang LI
Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
Type:
Application
Filed:
August 4, 2023
Publication date:
January 4, 2024
Applicant:
KEMIN INDUSTRIES, INC.
Inventors:
Geoffrey Paul HORST, Robert Bernard LEVINE
Abstract: The present invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin in the treatment and/or prevention of hepatic steatosis and related diseases. The invention also relates to the use of methyl cyclodextrin to reduce lipid accumulation in the liver.
Abstract: In an embodiment, the present disclosure pertains to a method to minimize infectivity and replication of an infection or reduce inflammation caused by the infection. Generally, the method includes administering a composition to a subject, where the composition includes a condensation polymer. In some embodiments, the method further includes at least one of binding, by the position, to a site on a virus, bacteria or fungi associated with the infection to thereby inhibit replication of the virus, bacteria, or fungi and reducing, by the composition, inflammation related to the infection. In another embodiment, the present disclosure pertains to a method to minimize infectivity and replication of a pathogen. Generally, the method includes applying a composition to clothing, where the composition includes a condensation polymer.
Type:
Application
Filed:
March 24, 2021
Publication date:
January 4, 2024
Inventors:
Barbara Best North, Michael Oldham, Donald Paul Waller, Mary Beth Weitzel
Abstract: An objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor, which has high bioavailability, low toxicity, and high therapeutic effectiveness, even when provided by oral administration. Another objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor which is effective in preventing or treating hepatic disorders. In order to achieve the above objectives, an acyl group is introduced into the primary amino group in the side chain of an ornithine unit in the poly(ornithine) segment of poly(ethylene glycol)-b-poly(ornithine), which spontaneously forms polymer micelles without polyion complex formation.
Type:
Application
Filed:
November 9, 2021
Publication date:
January 4, 2024
Applicant:
University of Tsukuba
Inventors:
Yukio NAGASAKI, Yaroslav LEE, Long Binh VONG, Yuta KODA, Yuanyuan DING
Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
Abstract: sodium borates are provided and alone as an active ingredient to prevent and/or treat fatty liver. In addition, the sodium borates reduce the expression levels of AADIPOR2, PRKAG2, IRS1, PIK3R1, NFKB1, MAP3K11, BID, CYCS, BAX, CASP3 and TGFB1 genes in the non-alcoholic fatty liver pathway and thereby to prevent and/or treat fatty liver by inhibiting the functioning of the non-alcoholic fatty liver pathway.
Abstract: The present invention relates to methods for expanding a population of alveolar macrophages in a long term culture. In particular, an object of the present invention relates to a method of expanding a population of alveolar macrophages in a long term culture comprising culturing the population of alveolar macrophages in a culture medium supplemented with an amount of GM-CSF.
Type:
Application
Filed:
April 28, 2023
Publication date:
January 4, 2024
Inventors:
Michael SIEWEKE, Kaaweh MOLAWI, Laufey GEIRSDOTTIR
Abstract: The present invention relates to the field of immunology and tumor treatment. Specifically, an Ras G12V mutant epitope peptide, an antigen presenting cell expressing the epitope peptide, a tumor vaccine containing same, and a use of the tumor vaccine in preventing or treating a tumor having RAS G12V mutation. The present invention further relates to a T cell receptor (TCR) specifically recognizing an Ras G12V mutant, a conjugate and a fusion protein containing the TCR, an immune cell expressing the TCR, a T cell drug containing same, and a use of the T cell drug in preventing or treating a tumor having RAS G12V mutation.
Abstract: The invention relates to nucleic acid constructs comprising a combination of a first sequence encoding a CAR and second sequence encoding an amino acid transporter, and to cells comprising such nucleic acid constructs. It also relates to methods of manufacturing said cells, and to pharmaceutical compositions comprising said nucleic acid constructs or cells, for use in the treatment of diseases with cellular amino-acid depletion such as cancer.
Abstract: Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Abstract: Disclosed herein is a method for enhancing adoptively transferred autologous or allogeneic immune effector cells (T cells) in patients who are HLA-C1+. In some embodiments, the method involves ablating KIR2DL2 expression in the T cells prior to adoptive transfer. In some embodiments, the T cells are further engineered to express a CAR. Therefore, disclosed herein are enhanced CAR-T cells that are engineered to have ablated KIR2DL2 expression or activity.
Type:
Application
Filed:
December 20, 2021
Publication date:
January 4, 2024
Inventors:
Daniel Abate-Daga, Miguel Gomez Fontela
Abstract: Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CD5) involve two chimeric antigen receptors (CARs) specific to CD33 and CD5 and T cells with CD33 and CD5 dual-CAR. Methods of administering a genetically modified T cell expressing the dual-CAR can be used for autologous and allogeneic treatment of T cell malignancies.
Abstract: The present disclosure provides BCMA-targeted chimeric antigen receptors (CARs) as well as preparation methods and applications thereof. The CARs of the present disclosure targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
Abstract: Provided herein are, among other things, methods for treating a patient suffering from a CD20+ cancer
Type:
Application
Filed:
December 16, 2021
Publication date:
January 4, 2024
Inventors:
Yu Kyeong Hwang, Jung Hyun Her, Yusun Kim, Eunji Kim, Hyojin Kim, Bitna Yang, Bokyung Min, Peter Flynn, Jason B. Litten, Thomas James Farrell, John Kin Chuan Lim, Mili Mandal
Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 ?M to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.
Type:
Application
Filed:
May 4, 2023
Publication date:
January 4, 2024
Inventors:
Michael TRAXLMAYR, Christian OBINGER, Charlotte BREY, Manfred LEHNER
Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses.
Abstract: Among the various aspects of the present disclosure are provisions for methods of, and compositions for, increasing NK cell anti-tumor response, screening donors, and predicting response to NK cell therapy.
Abstract: The present disclosure provides transposon-based systems for introducing cellular therapeutic products, such as CAR and TCR, into a target immune cell. The transposon-based systems can carry larger payloads than conventional viral vector-based technologies, simplifying multi-genetic editing and can reduce undesired recombination between homologous sequences in the payload. Also provided is a shortened autologous process that can be completed within a few days, within one day or even within a few hours. Even without immune cell activation, enrichment or expansion, the resulting cell populations achieve greatly higher in vivo therapeutic efficacy than the much lengthier autologous process that employs viral vectors.
Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
Type:
Application
Filed:
September 5, 2023
Publication date:
January 4, 2024
Applicant:
Precision BioSciences, Inc.
Inventors:
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Abstract: Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.
Type:
Application
Filed:
October 27, 2021
Publication date:
January 4, 2024
Applicant:
VOR BIOPHARMA INC.
Inventors:
Christopher Slapak, Glen Raffel, Michelle Lin, John Lydeard, Tirtha Chakraborty
Abstract: The present disclosure provides improved conditioning methods for use in hematopoietic stem cell transplantation and hematopoietic stem cell-based gene therapies.
Abstract: The present invention relates to a pharmaceutical composition for use in the prevention and/or the treatment of cancer and/or inflammation, comprising (i) a cellular and/or extracellular extract(s) obtained from a scaffold-free 3-dimensional culture of mature cells and a particulate material, wherein the mature cells secreted an extracellular matrix, and wherein the mature cells and the particulate material were embedded in the extracellular matrix; and (ii) a pharmaceutically acceptable excipient.
Abstract: This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.
Type:
Application
Filed:
July 11, 2023
Publication date:
January 4, 2024
Inventors:
John T. G. PENA, James Murray MITCHELL, Harmon Lawrence REMMEL
Abstract: Disclosed herein are methods and compositions for reducing inflammation in a subject. Aspects are directed to reduction of pulmonary inflammation using fibroblasts or fibroblast derived products. In some cases, fibroblasts or fibroblast-derived products are provided to a subject to reduce pulmonary inflammation, thereby treating or preventing airway allergy, asthma, or asthma-related symptoms. Embodiments encompass use of fibroblast-derived products, including exosomes, conditioned media, and other components derived from fibroblasts.